David A. Siegel Spring Works Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 24,500 shares of SWTX stock, worth $885,185. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,500
Previous 42,000
41.67%
Holding current value
$885,185
Previous $1.58 Million
50.44%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SWTX
# of Institutions
237Shares Held
68.9MCall Options Held
144KPut Options Held
257K-
Vanguard Group Inc Valley Forge, PA6.71MShares$243 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$203 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.84MShares$139 Million4.54% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.52MShares$127 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA3.42MShares$124 Million5.82% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.25B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...